Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Marker for diagnosing liver cancer and application thereof

A technology for liver cancer and its use, applied in the field of oncology and diagnosis, can solve the problems of increased negative proportion of AFP, unsatisfactory sensitivity and specificity, etc.

Active Publication Date: 2012-10-17
CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
View PDF4 Cites 10 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although alpha-fetoprotein plays a positive role in the diagnosis of liver cancer, its sensitivity and specificity are not satisfactory, and the proportion of AFP-negative cases in new cases is increasing

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Marker for diagnosing liver cancer and application thereof
  • Marker for diagnosing liver cancer and application thereof
  • Marker for diagnosing liver cancer and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 5

[0082] The above results indicated that, in clinical tissue samples of liver cancer, CYP17A1 mRNA and CYP17A1 protein were highly expressed in liver cancer.

[0083] In addition, the inventors also detected the expression of CYP17A1 in human serum by using enzyme-linked immunosorbent technology. The results showed that the expression of CYP17A1 in the serum of liver cancer patients was significantly higher than that of normal people[ Figure 5 , embodiment 6].

Embodiment 6

[0084] The average content of CYP17A1 protein in serum of normal people (n=30 cases) is 25.5 ng / ml, and the average content of serum of liver cancer patients (n=115 cases) is 115 ng / ml. Statistical analysis showed that there was a significant difference in the high expression of CYP17A1 protein in serum of liver cancer patients (P<0.001).

[0085]According to the 95% confidence interval of CYP17A1 content in normal human serum, when the CYP17A1 concentration is 34.5ng / ml as the cut-off point, the detection sensitivity and specificity can reach 86.1% and 70%, respectively. ROC curve analysis, the results are as follows Figure 5 As shown in B, the larger the area under the ROC curve in the figure, the higher the diagnostic value. The ROC curve area of ​​CYP17A1 is 0.889, which is significantly larger than the reference curve area of ​​0.5 (P<0.001), indicating that CYP17A1 is a serological molecular marker for liver cancer. It has good diagnostic value.

[0086] sample

[00...

Embodiment 2

[0125] In another preferred embodiment, the present invention also provides a CYP17A1 diagnostic kit, including: a CYP17A1 mRNA diagnostic kit [Example 2] or a CYP17A1 enzyme-linked immunosorbent immunoassay (ELISA) detection kit [Example 7].

[0126] The human liver cancer serological diagnosis kit of the present invention has completed hundreds of experiments, and the positive rate is about 70%.

[0127] The probability of liver cancer of the subjects who are tested positive by the serological diagnostic kit for human liver cancer of the present invention is obviously higher than that of normal population or general liver cancer patients.

[0128] pharmaceutical composition

[0129] The present invention also provides a pharmaceutical composition, which contains the above CYP17A1 antagonist and a pharmaceutically acceptable carrier. The pharmaceutical composition can be used to inhibit the growth of liver cancer cells.

[0130] In the present invention, the antagonist incl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a marker for detecting liver cancer and an application thereof, particularly the invention provides an application of 17 subfamily A polypeptide 1 (CYP17A1 protein) of the p450 family of cytochrome in preparing a diagnostic reagent or kit for detecting liver cancer. Studies show that CYP17A1expression quantity in liver cancer tissues is higher than that in peritumorial normal tissues, and CYP17A1 content in the serum of liver cancer patients is significantly higher than that in normal population. Accordingly, CYP17A1 can be used as the marker for detecting liver cancer (especially serological diagnosis). The present invention also provides a corresponding detection method and a kit. The method and the kit of the invention have good effect of serological diagnosis.

Description

technical field [0001] The present invention relates to the fields of oncology and diagnostics. More specifically, the present invention relates to a marker for diagnosing liver cancer and its use. Background technique [0002] Cytochrome P450 family 17 subfamily A polypeptide 1 (cytochrome P450, family 17, subfamily A, polypeptide 1, referred to as "CYP17A1"). The protein is also called 17alpha hydroxylase / 17, 20 carbon chain lyase, belongs to the cytochrome P450 enzyme system (cytochrome P450c17α enzyme), and consists of 508 amino acids. [0003] CYP17A1 protein is mainly located in the endoplasmic reticulum, and has steroid 17alpha monooxygenase, 17alpha hydroxylase and 17, 20 lyase activities. It is a key enzyme in the steroid hormone synthesis pathway. Participate in the production of substances including progesterone, mineralocorticoids, glucocorticoids, androgens, and estrogens. The mutation of CYP17A1 gene is accompanied by steroid-independent 17alpha hydroxylase...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/68C12Q1/26G01N33/574A61K48/00A61K39/395A61K45/00A61P35/00
CPCC12Q1/6886C07K16/40G01N33/57438G01N2333/80C12Q2600/112C12Q2600/158A61P35/00
Inventor 赵慕钧王峰邢振答亮许颖李载平
Owner CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com